Sarepta Therapeutics (NASDAQ:SRPT) Given New $50.00 Price Target at BMO Capital Markets

Key Points

• BMO Capital Markets has raised its price target for Sarepta Therapeutics from $25.00 to $50.00, indicating a potential upside of 202.06% from the current price.
• The company's stock has seen mixed ratings, with six analysts giving it a sell rating, seventeen a hold rating, and seven a buy rating, resulting in an average target price of $48.96.
• Sarepta Therapeutics reported a loss of ($3.42) EPS in its latest quarterly earnings, significantly missing analysts' expectations, despite achieving a revenue of $744.86 million for the quarter.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its target price upped by investment analysts at BMO Capital Markets from $25.00 to $50.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a "market perform" rating on the biotechnology company's stock. BMO Capital Markets' price objective would suggest a potential upside of 213.17% from the company's current price.

A number of other analysts have also recently issued reports on SRPT. Royal Bank Of Canada reduced their price objective on shares of Sarepta Therapeutics from $25.00 to $23.00 and set a "sector perform" rating for the company in a research note on Thursday, July 17th. HC Wainwright reissued a "sell" rating on shares of Sarepta Therapeutics in a research note on Tuesday. Robert W. Baird increased their price objective on shares of Sarepta Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. UBS Group reaffirmed a "neutral" rating on shares of Sarepta Therapeutics in a research note on Monday, July 21st. Finally, Sanford C. Bernstein began coverage on shares of Sarepta Therapeutics in a research note on Tuesday. They set a "market perform" rating and a $13.00 target price for the company. Six research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, Sarepta Therapeutics presently has an average rating of "Hold" and an average target price of $49.12.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT traded down $0.45 during midday trading on Tuesday, reaching $15.97. The stock had a trading volume of 2,801,752 shares, compared to its average volume of 5,726,139. The stock has a 50-day moving average of $24.24 and a 200-day moving average of $61.50. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.46 and a current ratio of 4.02. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of -5.95 and a beta of 0.45. Sarepta Therapeutics has a 12-month low of $10.41 and a 12-month high of $145.00.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The firm had revenue of $744.86 million during the quarter, compared to analysts' expectations of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The business's revenue for the quarter was up 80.2% on a year-over-year basis. During the same period last year, the company earned $0.73 earnings per share. As a group, research analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of large investors have recently made changes to their positions in SRPT. Byrne Asset Management LLC purchased a new position in shares of Sarepta Therapeutics during the 1st quarter worth about $30,000. Center for Financial Planning Inc. purchased a new position in shares of Sarepta Therapeutics during the 1st quarter worth about $31,000. Ancora Advisors LLC boosted its stake in shares of Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 300 shares during the period. Banque Transatlantique SA bought a new stake in Sarepta Therapeutics during the 1st quarter valued at about $44,000. Finally, Pandora Wealth Inc. bought a new stake in Sarepta Therapeutics during the 1st quarter valued at about $45,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.